The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.50
Ask: 10.00
Change: 0.00 (0.00%)
Spread: 1.50 (17.647%)
Open: 9.25
High: 9.25
Low: 9.25
Prev. Close: 9.25
NBB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options to Directors and Employees

18 Mar 2022 07:00

RNS Number : 1641F
Norman Broadbent PLC
18 March 2022
 

Norman Broadbent plc

("Norman Broadbent", "NBB" or the "Group")

Grant of Options to Directors and Employees

Norman Broadbent (AIM: NBB), a leading London quoted Executive Search and Interim Management firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services, announces that on 17 March 2022, the Group's Board of Directors agreed to a grant of 12,148,151 options over ordinary shares ("Options") to the Company's Executive Directors and certain employees under the Company's Enterprise Management Incentive Option Scheme 2022 (the "Scheme"). The options are exercisable at 0p (zero pence) per ordinary share.

The Options granted under the Scheme are subject to various conditions. They vest over a 4-year period (25 per cent. per year) starting 12 months after the date of the grant. No exercise can be made until at least 24 months from the date of the grant. Once vested, the Options can be exercised within 7 years of the grant date subject to two sets of performance criteria:

· 50 per cent. of the vested Options are exercisable on a scaled level following the share price of the Company achieving an average price of between 10p and 19p over any three-month period prior to 30 June 2026; and

 

· The remaining 50 per cent. of vested Options are exercisable on a scaled level following the achievement of audited EBITDA in the range of greater than £500,000 to £1,250,000 for any financial year of the Company from date of grant to 31 December 2025.

The following table sets out the details of the Options that have been granted to the Executive Directors:

Director

Share Price Vesting Options

EBITDA Vesting Options

Total Number of Options Granted

Total Number of Options Held

Percentage of Existing Issued Shares Under Option

Percentage of the Fully Diluted Share Capital*

Kevin Davidson

975,000

975,000

1,950,000

1,950,000

3.2%

2.7%

Peter Searle

500,000

500,000

1,000,000

1,000,000

1.6%

1.4%

Steve Smith

725,000

725,000

1,450,000

1,450,000

2.4%

2.0%

Total

2,200,000

2,200,000

4,400,000

4,400,000

7.2%

6.1%

 

*assuming that no further ordinary shares are issued by the Company between the date of this announcement and the exercise of the options.

Following the issue, options outstanding of 9,950,000 representing 16.4 per cent. of the current shares in issue. The Company has the ability to issue an additional 2,198,151 options under the scheme to a maximum of 20 per cent. of issued share capital. At the date of this announcement, the Company has 60,740,757 ordinary voting shares in issue.

Related Party Transactions

As Kevin Davidson, Peter Searle and Steve Smith, who are receiving options, are Directors of the Company, the grant of the aggregate number of Options to them constitutes a related party transaction as defined by the AIM Rules. Accordingly, the Independent Directors being Fiona McAnena, Angela Hickmore and Devyani Vaishampayan having consulted with WH Ireland Limited, the Company's Nominated Adviser, consider that the terms of this option grant are fair and reasonable insofar as shareholders are concerned.

The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation is appended further below.

Peter Searle, Executive Chairman of Norman Broadbent, commented:

"This options grant is a great opportunity for key team members across the Group to become beneficiaries of the future success of Norman Broadbent and, if the ambitious targets are achieved, will result in significant returns to all stakeholders. The Company's major shareholders are supportive of this grant and feel that this creates appropriate incentivisation to now align all parties in driving profitability and value in the business over the coming years."

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Kevin Davidson

Chief Executive Officer

Peter Searle

Executive Chairman

Steve Smith

Group CFO & COO

 

2

Reason for the notification

a)

Position/status

See 1a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Norman Broadbent Plc

b)

LEI

213800E5YN5TA934XA23

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of £0.01 each in Norman Broadbent Plc

Identification code (ISIN) for Norman Broadbent Plc ordinary shares: GB00B3VF4Y66

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Kevin Davidson

nil

1,950,000

Peter Searle

nil

1,000,000

Steve Smith

nil

1,450,000

 

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

Options put in place as of 17 March 2022

f)

Place of the transaction

Outside a trading venue

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For further information, please contact:

Norman Broadbent plc +44 (0) 20 7484 0000

Kevin Davidson

Peter Searle

Steve Smith

WH Ireland Limited +44 (0) 20 7220 1666

Jessica Cave

Darshan Patel

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFAFEWEESEID
Date   Source Headline
5th Apr 20117:00 amRNSDirectorate Change
31st Mar 20117:00 amRNSExercise of Warrants
3rd Dec 20107:00 amRNSExpansion into Psychological Assessment Services
15th Sep 20103:48 pmPRNDirector/PDMR Shareholding
14th Sep 201010:45 amPRNResult of General Meeting
14th Sep 20107:00 amRNSInterim Results
27th Aug 20109:47 amPRNPosting of Shareholder Circular
9th Aug 201011:00 amRNSShortage of Non-Executive Directors
28th Jul 20103:40 pmPRNResult of AGM
28th Jul 20107:00 amRNSTrading Update
12th Jul 20107:00 amPRNAdviser - change of name
30th Jun 201010:21 amPRNTotal Voting Rights
29th Jun 20107:01 amRNSDirectorate Changes
29th Jun 20107:00 amRNSFinal Results for the year ended 31 December 2009
15th Jun 20108:05 amRNSNotifiable Interest
14th Jun 201010:23 amRNSResults of General Meeting
14th Jun 20107:00 amRNSJoint Venture with Russam GMS
10th Jun 20105:03 pmPRNHolding(s) in Company
27th May 20107:00 amPRNCapital Reorganisation, Subscription and Change of Name
30th Mar 201010:09 amPRNTrading Statement
16th Mar 20107:00 amPRNChange of Registered Office
29th Jan 20107:00 amPRNTotal Voting Rights
28th Jan 20101:22 pmPRNIssue of Options
22nd Jan 20109:21 amPRNIssue of Equity
7th Jan 201012:17 pmPRNDirector/PDMR Shareholding
23rd Dec 20091:48 pmPRNChange of Adviser
27th Nov 20093:48 pmPRNTrading Statement
30th Sep 20092:09 pmPRNInterim Results
31st Jul 200910:44 amPRNTotal Voting Rights
23rd Jul 20092:59 pmPRNIssue of Equity
22nd Jul 20095:39 pmPRNResult of AGM
26th Jun 20097:30 amPRNFinal Results
31st Dec 20087:00 amRNSTotal Voting Rights
4th Dec 20087:00 amRNSAcquisition and Admission
3rd Dec 20087:53 amRNSCancellation - Garner Plc - Replacement
3rd Dec 20087:00 amRNSUpdate on Acquisition
2nd Dec 20083:46 pmRNSResult of EGM
19th Nov 200811:51 amRNSSchedule 1 - Garner Plc
7th Nov 20083:37 pmPRNAcquisition
30th Sep 20087:00 amPRNHalf-yearly Report
21st May 20084:57 pmPRNResult of AGM
21st May 20084:53 pmPRNLaunch Of HR Practice
30th Apr 20082:27 pmPRNTotal Voting Rights
7th Apr 20081:42 pmPRNAdviser Change of Name
31st Mar 20088:01 amPRNChange of Adviser
31st Mar 20088:00 amPRNFinal Results
20th Dec 200710:38 amPRNDirector Dealing / Grant of Options
22nd Nov 20074:57 pmPRNDirector/PDMR Shareholding
1st Oct 200712:29 pmPRNDirector/PDMR Shareholding
20th Sep 20071:59 pmPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.